ReviewTherapeutic advances in gastroenterology2021
The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management.
Review in Therapeutic advances in gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Review
- Immunomodulators, Biologics, and 5-ASA for Inflammatory Bowel Disease and Major Adverse Cardiovascular Events in Older Adults.JAMA network open · 2026Article
- Exploring the Link Between Inflammatory Bowel Disease and Chronic Kidney Disease: A Nationwide Database Study.Journal of clinical medicine · 2026Article
- Clinical characteristics and prognostic differences between elderly-onset and adult-onset ulcerative colitis: a two-center retrospective cohort study.Frontiers in medicine · 2026Article
- Ulcerative colitis (UC) in the elderly: diagnostic and therapeutic considerations.Frontiers in aging · 2026Review
- The Efficacy and Safety of Thiopurines Do Not Differ Between Geriatric and Non-Geriatric Patients with Inflammatory Bowel Disease.International journal of medical sciences · 2026Article
- Gut microbial Nordihydroguaiaretic acid suppresses macrophage pyroptosis to regulate epithelial homeostasis and inflammation.Gut microbes · 2025Article
- Elderly-Onset Inflammatory Bowel Disease Has Distinct Disease Characteristics and Treatment Patterns.United European gastroenterology journal · 2025Article
- Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective Study.Journal of gastroenterology and hepatology · 2025Observational
- Cellular senescence defining the disease characteristics of Crohn's disease.Frontiers in immunology · 2025Article
- The role and intrinsic connection of cellular senescence and cell death in inflammatory bowel disease.Frontiers in cell and developmental biology · 2025Review
- Role of Aging in Ulcerative Colitis Pathogenesis: A Focus on ETS1 as a Promising Biomarker.Journal of inflammation research · 2025Article
- Advanced Therapies in Elderly Patients With Inflammatory Bowel Disease: A Comparative Retrospective Cohort Study in Taiwan.Therapeutics and clinical risk management · 2025Article
- Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases.Journal of Crohn's & colitis · 2024Review
- Safety and Effectiveness of Thiopurines and Small Molecules in Elderly Patients with Inflammatory Bowel Diseases.Journal of clinical medicine · 2024Review
- Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study.Journal of clinical medicine · 2024Article
- Management Considerations for the Older Adult With Inflammatory Bowel Disease.Gastroenterology & hepatology · 2023Article
- Review
- Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients.World journal of gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence and prevalence of inflammatory bowel disease (IBD) is rising in the elderly population. Compared with patients with onset during their younger years, patients with elderly onset IBD have a distinct clinical presentation, disease phenotype, and natural history. Genetics contribute less to pathogenesis of disease, whereas biological changes associated with aging including immunosenescence, dysbiosis, and frailty have a greater impact on disease outcomes. With the advent of an increasingly wider array of biologic and small-molecule therapeutic options, data regarding efficacy and safety of these agents in elderly IBD patients specifically are paramount, given the unique characteristics of this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.